

STAMPEDE Abiraterone volume analysis (n= 901)	LATITUDE criteria						CHAARTED Criteria					
	Low Risk (n=428)			High Risk (n=473)			Low Risk (n=402)			High Risk (n=499)		
	ADT (n=220)	ADT+AAP (n=208)	p-value	ADT (n=232)	ADT+AAP (n=241)	p-value	ADT (n=196)	ADT+AAP (n=206)	p-value	ADT (n=256)	ADT+AAP (n=243)	p-value
Age at randomization												
Median	66	66	0.37	67	67	0.75	67	66	0.14	67	68	0.36
IQR	62-72	62-71		63-72	63-71		63-72	61-71		62-72	64-72	
PSA prior to ADT												
Median	51	70	0.14	174	126	0.28	45	53	0.19	177	174	0.94
IQR	19-148	24-198		40-735	36-458		16-121	20-132		45-786	55-657	
WHO performance status												
0	174	158	0.44	163	177	0.44	155	164	0.90	182	171	0.86
1-2	46	50		69	64		41	42		74	72	
Gleason Sum												
<=7	107	102	0.93	3	2	0.62	54	61	0.65	56	43	0.24
8-10	113	106		229	239		142	145		200	200	
Primary Tumour stage												
≤T2	26	23	0.50	23	21	0.32	19	22	0.97	30	22	0.22
T3	133	125		116	141		120	122		129	144	
T4	54	47		68	59		46	49		76	57	
TX	7	13		25	20		11	13		21	20	
Regional node status												
N0	80	66	0.49	78	84	0.36	61	67	0.92	97	83	0.37
N+	125	130		137	131		122	127		140	134	
NX	15	12		17	26		13	12		19	26	
Eligibility												
M+, new	202	190	0.86	229	238	0.96	182	191	0.96	249	237	0.85
Previously treated	18	18		3	3		14	15		7	6	
Metastatic Site												
Node	47	55	0.55	-	-	0.77	47	55	0.61	-	-	0.89
Bone	140	127		154	169		116	123		178	173	
Visceral	1	1		1	-		-	-		2	1	
Bone + Node	32	24		60	52		33	28		59	48	
Bone + Visceral	-	-		9	12		-	-		9	12	
Visceral + Node	-	-		1	1		-	-		1	1	
Bone + Node + Visceral	-	1		7	7		-	-		7	8	